MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1055/a-0895-5138

Медицинская библиотека · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2019

Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease.

Rickli Cristiane, Borato Danielle Cristyane Kalva, Silva Anderson José de Melo E, Schuinski Adriana Fatima Menegat, Vilela Gustavo Henrique Frigieri, Vellosa José Carlos Rebuglio

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). Elevated serum concentrations of myeloperoxidase (MPO) are associated with an increased risk of developing CVD. The objective of this study was to evaluate serum MPO levels, as well as other laboratory parameters, in individuals with ESRD, with and without CVD, undergoing hemodialysis.

METHODS

80 volunteers were admitted, divided into the following groups: control group (CON): 20 individuals without chronic kidney disease (CKD); ESRD group: 45 individuals with CKD stage V and ESRD/CVD group: 15 individuals with CKD stage V and with CVD. The following biomarkers were evaluated: MPO, High sensitivity C-reactive protein (hs-CRP) and α1-acid glycoprotein, following the manufacturer's guidelines in the package inserts. The data were processed through the statistical software SPSS 20.0®.

RESULTS

The level of MPO for the CON group was 84 ng/mL (73-87 ng/mL), for the ESRD group 77 ng/mL (11-89 ng/mL) and for the ESRD/CVD group 21 ng/mL (8-47 ng/mL), with a significant statistical difference of the ESRD/CVD group from the CON and ESRD groups (p<0.001). For the parameters hs-CRP and α1-acid glycoprotein a statistical difference between the ESRD and ESRD/CVD groups from the CON group (p<0.0001) was observed, but not between the ESRD and ESRD/CVD groups.

CONCLUSION

It is suggested that further studies should be performed to define the potential role of MPO as a cardiovascular risk marker for patients with ESRD on hemodialysis.

Для цитирования: Rickli Cristiane, Borato Danielle Cristyane Kalva, Silva Anderson José de Melo E, Schuinski Adriana Fatima Menegat, Vilela Gustavo Henrique Frigieri, Vellosa José Carlos Rebuglio. Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease.. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2019. DOI: 10.1055/a-0895-5138.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.